DarioHealth Corp 2026年季度报告

FORM10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIES EXCHANGE ACTOF 1934 For the quarterly period ended March 31, 2026 ☐TRANSITION REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIES EXCHANGE ACTOF 1934 Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d)of theSecurities Exchange Act of 1934 during the preceding 12months (or for such shorter period that the registrant wasrequired to file such reports), and (2)has been subject to such filing requirements for the past 90days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12months (or for suchshorter period that the registrant was required to submit such files). Yes☒No☐Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “acceleratedfiler,” “smaller reporting company,” and “emerging growth company” in Rule12b-2 of the Exchange Act. ☐Large accelerated filer☒Non-accelerated filer ☐Accelerated filer☒Smaller reporting company☐Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transitionperiod for complying with any new or revised financial accounting standards provided pursuant to Section13(a)of theExchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act).Yes☐No☒ As of May 12, 2026, the registrant had 7,312,398 shares of common stock outstanding. When used in this quarterly report, the terms “Dario,” “DarioHealth,” “the Company,” “we,” “our,” and “us” referto DarioHealth Corp., a Delaware corporation and our subsidiary LabStyle Innovation Ltd., an Israeli company,PsyInnovations Inc., a Delaware corporation, Twill, Inc., a Delaware corporation, and DarioHealth India Services Pvt.Ltd., an Indian company. Dario is registered as a trademark in the United States, China, Canada, Hong Kong, Australia,Brazil, the EU, and is also registered as a WO (WIPO registration). “DarioHealth” is registered as a trademark in theUnited States, Israel, China, Canada, Australia, India, Japan, the EU, and as a WO. DarioHealth Corp. Quarterly Report on Form10-Q TABLE OF CONTENTS Cautionary Note Regarding Forward-Looking Statements4PART1 - FINANCIAL INFORMATIONItem 1.Condensed Consolidated Interim Financial Statements(unaudited)F-1Condensed Consolidated Interim Balance Sheets (Unaudited)F-2 – F-3Condensed Consolidated Interim Statements of Comprehensive Loss (Unaudited)F-4Condensed Consolidated Interim Statements of Changes in Stockholders’ Equity(Unaudited)F- 5 – F-5Condensed Consolidated Interim Statements of Cash Flows (Unaudited)F-6Notes to Condensed Consolidated Interim Financial StatementsF-7 – F-20Item 2.Management’s Discussion and Analysis of Financial Condition and Results ofOperations4Item 4.Control and Procedures11PARTII - OTHER INFORMATION12Item 1A. Risk Factors12Item 6.Exhibits13SIGNATURES14 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Certain information set forth in this Quarterly Report on Form10-Q, including in Item 2,“Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhereherein may address or relate to future events and expectations and as such constitutes “forward-lookingstatements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements whichare not historical reflect our current expectations and projections about our future results, performance,liquidity, financial condition, prospects and opportunities and are based upon information currentlyavailable to us and our management and their interpretation of what is believed to be significant factorsaffecting our business, including many assumptions regarding future events. Such forward-lookingstatements include statements regarding, among other things: ●our current and future capital requirements and our ability to satisfy our capital needs throughfinancing transactions or otherwise;●our ability to meet the requirements of our existing debt facility;●our product launches and market penetration plans;●the execution of agreements with various providers for our solution;●our ability to maintain our relationships with key partners;●our ability to maintain or protect the validity of our U.S. and other patents and other intellectualproperty;●our ability to retain key executive members;●our ability to internally develop new inventions and intellectual property;●that our financial position raises substantial doubt about our ability to continue as a goingconcern;●the ability to consummate a potential sale, merger or strategic business com